The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
Open accessAbstract
The recent identification of “side population” (SP) cells in a number of unrelated human cancers and their normal tissue sources has renewed interest in the hypothesis that cancers may arise from somatic stem/progenitor cells. The high incidence of recurrence attributable to multidrug resistance and the multiple histologic phenotypes indicative of multipotency suggests a stem cell-like etiology of ovarian cancer. Here we identify and characterize SP cells from two distinct genetically engineered mouse ovarian cancer cell lines. Differential efflux of the DNA-binding dye Hoechst 33342 from these cell lines defined a human breast cancer-resistance protein 1-expressing, verapamil-sensitive SP of candidate cancer stem cells. In vivo , mouse SP cells formed measurable tumors sooner than non-SP (NSP) cells when equal numbers were injected into the dorsal fat pad of nude mice. The presence of Mullerian Inhibiting Substance (MIS) signaling pathway transduction molecules in both SP and NSP mouse cells led us to investigate the efficacy of MIS against these populations in comparison with traditional chemotherapies. MIS inhibited the proliferation of both SP and NSP cells, whereas the lipophilic chemotherapeutic agent doxorubicin more significantly inhibited the NSP cells. Finally, we identified breast cancer-resistance protein 1-expressing verapamil-sensitive SPs in three of four human ovarian cancer cell lines and four of six patient primary ascites cells. In the future, individualized therapy must incorporate analysis of the stem cell-like subpopulation of ovarian cancer cells when designing therapeutic strategies for ovarian cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Rapid colorimetric assay for cell growth and survival
Denizot, F., & Lang, R. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90368-6 · Cited by 4,935
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.
Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., & Mulligan, R. C. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1797 · Cited by 2,903
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,003
A distinct “side population” of cells with high drug efflux capacity in human tumor cells
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A., & Brenner, M. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400067101 · Cited by 1,280
STEM CELL NICHE: Structure and Function
Li, L., & Xie, T. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.012704.131525 · Cited by 1,229
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Austin Doyle, L., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,051
Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line
Kondo, T., Setoguchi, T., & Taga, T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307618100 · Cited by 985
Stem cell origin of cancer and differentiation therapy
Sell, S. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.04.007 · Cited by 638
Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D., & Jacks, T. (2005) · Nature Medicine · doi:10.1038/nm1173 · Cited by 604
Self-citationCharacterization of a Side Population of Cancer Cells from Human Gastrointestinal System
Haraguchi, N., Utsunomiya, T., Inoue, H., Tanaka, F., Mimori, K., Barnard, G. F., & Mori, M. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0282 · Cited by 569
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
Wulf, G. G., Wang, R.-Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M. K., Andreeff, M., & Goodell, M. A. (2001) · Blood · doi:10.1182/blood.v98.4.1166 · Cited by 326
Connolly, D. C., Bao, R., Nikitin, A. Y., Stephens, K. C., Poole, T. W., Xiang, H., Harris, S. S., Vanderhyden, B. C., & Hamilton, T. C. (2003) · PubMed · Cited by 310
Self-citationCannistra, S. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292108 · Cited by 291
Recent progress in ovarian cancer
Scully, R. E. (1970) · Human Pathology · doi:10.1016/s0046-8177(70)80005-3 · Cited by 236
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer
Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, A. J., Ozols, R. F., Fojo, A. T., & Hamilton, T. C. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450306 · Cited by 185
Stem-cell origin of metastasis and heterogeneity in solid tumours
Tu, S.-M., Lin, S.-H., & Logothetis, C. J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00820-3 · Cited by 179
Duan, Z., Brakora, K. A., & Seiden, M. V. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.833.3.7 · Cited by 171
Cancer stem cell characteristics in retinoblastoma.
Seigel, G. M., Campbell, L. M., Narayan, M., & Gonzalez-Fernandez, F. (2005) · PubMed · Cited by 171
Penson, R. T., Oliva, E., Skates, S. J., Glyptis, T., Fuller, A. F., Goodman, A., & Seiden, M. V. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.053 · Cited by 161
FURTHER EVIDENCE FAVORING THE CONCEPT OF THE STEM CELL IN ASCITES TUMORS OF RATS
Makino, S. (1956) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1956.tb50894.x · Cited by 152
Will cancer stem cells provide new therapeutic targets?
Behbod, F., & Rosen, J. M. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh293 · Cited by 152
Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases.
Poste, G. H., Tzeng, J., Doll, J., GREIG, R. G., Rieman, D. J., & Zeidman, I. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.21.6574 · Cited by 138
Seiden, M. V., Swenerton, K. D., Matulonis, U. A., Campos, S., Rose, P. G., Batist, G., Ette, E., Garg, V., Fuller, A., Harding, M. W., et al. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6762 · Cited by 98
Müllerian Inhibiting Substance Inhibits Ovarian Cell Growth through an Rb-independent Mechanism
Ha, T. U., Segev, D. L., Barbie, D. A., Masiakos, P. T., Tran, T. T., Dombkowski, D., Glander, M., Clarke, T. R., Lorenzo, H. K., Donahoe, P. K., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005701200 · Cited by 98
Self-citationOverexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype.
Duan, Z., Lamendola, D. E., Yusuf, R., Penson, R. T., Preffer, F. I., & Seiden, M. V. (2002) · PubMed · Cited by 83
Self-citationZhan, Y., Fujino, A., MacLaughlin, D. T., et al. (2006) · Development · doi:10.1242/dev.02383 · Cited by 75
Self-citationPreffer, F. I., Dombkowski, D., Sykes, M., Scadden, D. T., & Yang, Y. (2002) · Stem Cells · doi:10.1634/stemcells.20-5-417 · Cited by 57
Self-citationPieretti‐Vanmarcke, R., Donahoe, P. K., Szotek, P. P., Manganaro, T. F., Lorenzen, M. K., Lorenzen, J., Connolly, D. C., Halpern, E. F., & MacLaughlin, D. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2108 · Cited by 50
Self-citation
Cited by
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Metadata
- Authors
- Szotek, P. P., Pieretti-Vanmarcke, R., Masiakos, P. T., Dinulescu, D. M., Connolly, D., Foster, R., Dombkowski, D., Preffer, F., MacLaughlin, D. T., & Donahoe, P. K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-07-25
- Volume
- 103
- Issue
- 30
- Pages
- 11154-11159
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2163368401
- Cited by
- 751
- References
- 34
- FWCI
- 25.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.